AFATINIB IN THE TREATMENT OF METASTATIC AND LOCALLY ADVANCED LUNG ADENOCARCINOMA WITH EGFR MUTATIONS: NEW SIDES STUDIED POSSIBILITIES

A reasonable strategy for drug therapy of non-small-cell lung cancer  (NSCLC) with activating mutations of EGFR is the use of tyrosine kinase inhibitors (TKI) in front-line therapy, providing a two-fold increase in life expectancy for patients with metastatic or locally advanced form of the disease....

ver descrição completa

Detalhes bibliográficos

Principais autores:	E. V. Karabina, L. N. Lubchenko, M. M. Davydov
Formato:	Artigo
Idioma:	Russo
Publicado em:	Remedium Group LLC 2017-11-01
coleção:	Медицинский совет
Assuntos:	locally advanced and metastatic non-small cell lung cancer adenocarcinoma of the lung tyrosine kinase inhibitors of egfr egfr-activating mutations targeted therapy resistance afatinib
Acesso em linha:	https://www.med-sovet.pro/jour/article/view/2166
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!